+228.1%
AEHR vs GSK
+31.2%
+196.9%
-47.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +13.1% | -1.9% | +15.0% | +13.1% |
| 7D | +6.7% | -1.8% | +8.6% | +6.7% |
| 30D | -12.7% | -2.2% | -10.5% | -12.7% |
| 3M | -26.0% | -1.8% | -24.2% | -26.6% |
| 6M | +102.2% | -10.6% | +112.8% | +105.5% |
| YTD | +327.2% | +4.4% | +322.8% | +310.5% |
| 1Y | +228.1% | +30.4% | +197.7% | +169.7% |
| All | +228.1% | +31.2% | +196.9% | +169.7% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling